These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 23177109)
1. Quantitative and volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors measurements: feasibility of a semiautomated software method to assess tumor response after transcatheter arterial chemoembolization. Lin M; Pellerin O; Bhagat N; Rao PP; Loffroy R; Ardon R; Mory B; Reyes DK; Geschwind JF J Vasc Interv Radiol; 2012 Dec; 23(12):1629-37. PubMed ID: 23177109 [TBL] [Abstract][Full Text] [Related]
2. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach. Tacher V; Lin M; Duran R; Yarmohammadi H; Lee H; Chapiro J; Chao M; Wang Z; Frangakis C; Sohn JH; Maltenfort MG; Pawlik T; Geschwind JF Radiology; 2016 Jan; 278(1):275-84. PubMed ID: 26131913 [TBL] [Abstract][Full Text] [Related]
3. Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma. Bonekamp D; Bonekamp S; Halappa VG; Geschwind JF; Eng J; Corona-Villalobos CP; Pawlik TM; Kamel IR Eur J Radiol; 2014 Mar; 83(3):487-96. PubMed ID: 24387824 [TBL] [Abstract][Full Text] [Related]
4. Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis. Chapiro J; Wood LD; Lin M; Duran R; Cornish T; Lesage D; Charu V; Schernthaner R; Wang Z; Tacher V; Savic LJ; Kamel IR; Geschwind JF Radiology; 2014 Dec; 273(3):746-58. PubMed ID: 25028783 [TBL] [Abstract][Full Text] [Related]
5. Baseline and Early MR Apparent Diffusion Coefficient Quantification as a Predictor of Response of Unresectable Hepatocellular Carcinoma to Doxorubicin Drug-Eluting Bead Chemoembolization. Kokabi N; Ludwig JM; Camacho JC; Xing M; Mittal PK; Kim HS J Vasc Interv Radiol; 2015 Dec; 26(12):1777-86. PubMed ID: 26603497 [TBL] [Abstract][Full Text] [Related]
6. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL? Zhao Y; Duran R; Bai W; Sahu S; Wang W; Kabus S; Lin M; Han G; Geschwind JF Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058 [TBL] [Abstract][Full Text] [Related]
7. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers. Chapiro J; Duran R; Lin M; Schernthaner RE; Wang Z; Gorodetski B; Geschwind JF Radiology; 2015 May; 275(2):438-47. PubMed ID: 25531387 [TBL] [Abstract][Full Text] [Related]
8. Response assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization. Adam LC; Savic LJ; Chapiro J; Letzen B; Lin M; Georgiades C; Hong KK; Nezami N Clin Imaging; 2022 Sep; 89():112-119. PubMed ID: 35777239 [TBL] [Abstract][Full Text] [Related]
9. Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning-An Artificial Intelligence Concept. Abajian A; Murali N; Savic LJ; Laage-Gaupp FM; Nezami N; Duncan JS; Schlachter T; Lin M; Geschwind JF; Chapiro J J Vasc Interv Radiol; 2018 Jun; 29(6):850-857.e1. PubMed ID: 29548875 [TBL] [Abstract][Full Text] [Related]
10. Multimodality 3D Tumor Segmentation in HCC Patients Treated with TACE. Wang Z; Chapiro J; Schernthaner R; Duran R; Chen R; Geschwind JF; Lin M Acad Radiol; 2015 Jul; 22(7):840-5. PubMed ID: 25863795 [TBL] [Abstract][Full Text] [Related]
11. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy. Bonekamp S; Halappa VG; Geschwind JF; Li Z; Corona-Villalobos CP; Reyes D; Bhagat N; Cosgrove DP; Pawlik TM; Mezey E; Eng J; Kamel IR Radiology; 2013 Aug; 268(2):431-9. PubMed ID: 23616632 [TBL] [Abstract][Full Text] [Related]
12. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer. Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641 [TBL] [Abstract][Full Text] [Related]
13. Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study. Kokabi N; Camacho JC; Xing M; Edalat F; Mittal PK; Kim HS J Magn Reson Imaging; 2015 Oct; 42(4):981-9. PubMed ID: 25683022 [TBL] [Abstract][Full Text] [Related]
14. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma. Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378 [TBL] [Abstract][Full Text] [Related]
15. Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver. Chapiro J; Duran R; Lin M; Schernthaner R; Lesage D; Wang Z; Savic LJ; Geschwind JF Eur Radiol; 2015 Jul; 25(7):1993-2003. PubMed ID: 25636420 [TBL] [Abstract][Full Text] [Related]
16. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up. Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569 [TBL] [Abstract][Full Text] [Related]
18. Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinoma. Wang D; Gaba RC; Jin B; Riaz A; Lewandowski RJ; Ryu RK; Sato KT; Ragin AB; Kulik LM; Mulcahy MF; Salem R; Larson AC; Omary RA Acad Radiol; 2011 Jul; 18(7):828-36. PubMed ID: 21669349 [TBL] [Abstract][Full Text] [Related]
19. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Reyes DK; Vossen JA; Kamel IR; Azad NS; Wahlin TA; Torbenson MS; Choti MA; Geschwind JF Cancer J; 2009; 15(6):526-32. PubMed ID: 20010173 [TBL] [Abstract][Full Text] [Related]
20. Transarterial Chemoembolization of Hepatocellular Carcinoma Using Radiopaque Drug-Eluting Embolics: How to Pursue Periprocedural Cross-Sectional Imaging? Ruff C; Grözinger G; Syha R; Elser S; Partovi S; Bitzer M; Horger M; Nikolaou K; Grosse U J Vasc Interv Radiol; 2019 Mar; 30(3):380-389.e4. PubMed ID: 30819480 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]